# Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

> **NCT05030246** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 72 (estimated)

## Conditions studied

- Refractory Metastatic Digestive System Carcinoma
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** Surufatinib/Toripalimab

## Key facts

- **NCT ID:** NCT05030246
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-14
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2021-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05030246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05030246, "Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05030246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*